Overcoming functional and translational challenges of cellular immunotherapies for solid tumors

A comprehensive review published in Cancer Cell by Chen et al. examines the major barriers preventing cellular immunotherapies — including CAR-T and other engineered cell-based treatments — from replicating their success in blood cancers when applied to solid tumors. The authors systematically assess functional impediments such as the immunosuppressive tumor microenvironment, antigen heterogeneity, and T-cell exhaustion, as well as translational challenges including manufacturing complexity for both autologous and allogeneic approaches. The review highlights emerging engineering advances and novel technologies that may enable next-generation cellular therapies to overcome these obstacles. While no new experimental data are presented, the paper provides a valuable roadmap for researchers and clinicians working to extend the promise of cell therapy to the far larger population of patients with solid malignancies.